newsfilter
← Latest News
GlobeNewswire·

Adagene Announces Completion of Enrollment in Randomized Dose Optimization Phase 2 Trial of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer

- Enrollment of 60 patients complete; initial results expected in 1H 2027 to inform dose regimen for the Phase 3 trial- Adagene continues to own worldwide commercial rights to muzastotug SAN DIEGO and SUZHOU, China,